Summary | |
---|---|
Symbol | STK31 |
Name | serine/threonine kinase 31 |
Aliases | TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ...... |
Chromosomal Location | 7p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | - |
Domain |
PF00069 Protein kinase domain PF00567 Tudor domain |
Function |
- |
Biological Process |
GO:0006401 RNA catabolic process GO:0019439 aromatic compound catabolic process GO:0034655 nucleobase-containing compound catabolic process GO:0044270 cellular nitrogen compound catabolic process GO:0046700 heterocycle catabolic process GO:0090305 nucleic acid phosphodiester bond hydrolysis GO:1901361 organic cyclic compound catabolic process |
Molecular Function |
GO:0004518 nuclease activity GO:0004674 protein serine/threonine kinase activity |
Cellular Component |
GO:0001669 acrosomal vesicle GO:0030141 secretory granule GO:0097223 sperm part GO:0099503 secretory vesicle |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | STK31 |
Name | serine/threonine kinase 31 |
Aliases | TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ...... |
Chromosomal Location | 7p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between STK31 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between STK31 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | STK31 |
Name | serine/threonine kinase 31 |
Aliases | TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ...... |
Chromosomal Location | 7p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of STK31 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | STK31 |
Name | serine/threonine kinase 31 |
Aliases | TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ...... |
Chromosomal Location | 7p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of STK31 in various data sets.
|
Points in the above scatter plot represent the mutation difference of STK31 in various data sets.
|
Summary | |
---|---|
Symbol | STK31 |
Name | serine/threonine kinase 31 |
Aliases | TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ...... |
Chromosomal Location | 7p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STK31. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | STK31 |
Name | serine/threonine kinase 31 |
Aliases | TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ...... |
Chromosomal Location | 7p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STK31. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STK31. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | STK31 |
Name | serine/threonine kinase 31 |
Aliases | TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ...... |
Chromosomal Location | 7p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STK31. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | STK31 |
Name | serine/threonine kinase 31 |
Aliases | TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ...... |
Chromosomal Location | 7p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of STK31 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | STK31 |
Name | serine/threonine kinase 31 |
Aliases | TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ...... |
Chromosomal Location | 7p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between STK31 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | STK31 |
Name | serine/threonine kinase 31 |
Aliases | TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ...... |
Chromosomal Location | 7p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting STK31 collected from DrugBank database. |
There is no record. |